TROY, N.Y., Oct. 20 /PRNewswire/ -- Evident Technologies, Inc., a pioneer in the development of advanced quantum dot nanomaterials, today announced the company has added a top sales executive and expanded both its own sales force and its global distribution network.
“To meet the growing demands for all of our nanomaterial products, we have added a new Vice President for Sales, Jeffrey Goronkin, who has extensive business development and sales experience in the life science field,” said Clinton Ballinger, Ph.D., Evident’s Chief Executive Officer.
Prior to joining Evident, Goronkin held the position of Senior Commercial Manager for Proligo, LLC, a Degussa company, where he rebuilt the sales organization prior to its acquisition by Sigma-Aldrich. At Proligo, Goronkin was also responsible for securing multi-million dollar phosphoramidite business for applications in the synthetic DNA/RNA research and therapeutic industries. Before joining Proligo, Goronkin was Manager of Corporate Development for Integrated DNA Technologies where he was responsible for new business opportunities in the oligonucleotide market. Goronkin has a bachelor’s degree in Biology from the University of Arizona.
“Jeff’s track record of building strong sales teams and opening new markets will further accelerate Evident’s expanding product development,” said Ballinger. “To support this growth, we have also tripled our sales staff, added regional sales representatives in targeted areas of the country, and have a growing number of agreements with major distributors and value added resellers in the United States, Europe, Japan, and throughout Asia.”
Currently, Evident has six major product lines in development or on the market for commercial sales. These products -- dots, resins, particles, powders, tags and fluorescing probes -- have applications across a number of markets. In addition, the company recently announced the release of its new non-heavy metal quantum dot T2-MP EviTags(TM).
“We believe these non-heavy metal EviTags could provide the foundation for the future of quantum dot nanomaterials,” said Ballinger.
Evident’s proprietary T2-MP EviTag(TM) product line is based on a new type of Indium Gallium Phosphide (InGaP) quantum dots that are coated with an outer layer of zinc sulphide deposited via Evident’s proprietary ‘Molecular Plating’ technique. The presence of this outer protective layer produces a bright, stable, non-heavy metal quantum dot-based fluorescent label with reduced toxicity that can enable a wide variety of novel life science applications ranging from clinical diagnostics to cell microscopy and in vivo imaging. The T2-MP EviTags(TM) can also be used for bio-threat detection and a broad spectrum of optoelectronic applications such as solar cells, flat panel displays and light emitting diodes. In addition, because they do not contain cadmium or lead, which are found in traditional quantum dots, they are not subject to the restrictions that Japan and European countries have imposed on the use of heavy metals, particularly for consumer devices.
About Evident Technologies
Evident Technologies (http://www.evidenttech.com) is a pioneer in the development of advanced quantum dot nanomaterials engineered to enable next-generation products for numerous markets including life sciences, solid-state lighting, energy, security, telecommunications and emergent nanotechnology markets. Evident is a leading commercial source for a wide range of quantum dot material systems and a partner-of-choice for companies in a growing range of markets.
Evident Technologies, Inc.
CONTACT: Steven Talbot, CMO of Evident Technologies, +1-518-273-6266,stalbot@evidenttech.com
Web site: Http://www.evidenttech.com/
